Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

Posted On: 2018-01-18 04:27:17

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia's premier biopharmaceuticals company, and Sandoz, a Novartis division and a global leader in biosimilars, today announced a global partnership to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally. Worldwide commercialization responsibilities will be divided and each company's strengths will be leveraged within specific geographies. Sandoz will lead commercialization in North America* and the EU** while Biocon will lead commercialization in Rest of the World.***

Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: "We are pleased to announce our collaboration with Sandoz for developing a set of next generation biosimilar products. This synergistic partnership will enable us to scale up our capabilities for an end to end play in the global biosimilars space. We remain committed to pursue our mission of developing biopharmaceuticals that have the potential to benefit a billion patients across the globe."

Dr. Arun Chandavarkar, CEO & Joint MD, Biocon, added: "Biocon has worked at the leading edge of science and has demonstrated its capabilities in developing high quality biosimilars. Our credibility has been further endorsed by the recent USFDA approval of our Biosimilar Trastuzumab, which is also the first in the US. Our collaboration with Sandoz will bolster our existing global biosimilars portfolio comprising biosimilar antibodies & insulin analogs and will enable us to address the next wave of global biosimilars opportunities."

As an innovation-led biopharmaceutical company, Biocon has successfully developed and taken a range of novel biologics, biosimilar antibodies, rh-insulin and insulin analogs from 'lab to market'. The collaboration with Sandoz builds upon Biocon's successful progress in its existing global biosimilars program. The most recent USFDA approval of the first biosimilar of Trastuzumab, marks an important milestone for Biocon as it is also the first biosimilar to be approved in the US for any Company from India. An early mover in the biosimilars space, Biocon has successfully launched its insulin glargine in Japan, Trastuzumab & Bevacizumab biosimilars in India and rh-Insulin, Insulin Glargine and biosimilar Trastuzumab in few emerging markets.

Sandoz is committed to increasing patient access to high-quality biosimilars and has five biosimilars currently marketed worldwide, as well as a rich global pipeline. Sandoz is well placed to strengthen its position in the biosimilars space based on its experience and capabilities in development, manufacturing and commercialization. As a division of Novartis, the first global healthcare company to establish a leading position in both innovative and off-patent medicines, Sandoz benefits strongly from this unique blend of experience and expertise in many different market environments.

Biocon's collaboration with Sandoz addresses some of the biosimilar opportunities beyond the near term opportunities being addressed by Biocon's existing successful global partnership with Mylan. This new partnership is a significant milestone in Biocon's journey of developing advanced therapies that have the potential to benefit billions of patients.

Shares of BIOCON LTD. was last trading in BSE at Rs.539.6 as compared to the previous close of Rs. 551. The total number of shares traded during the day was 163805 in over 2443 trades.

The stock hit an intraday high of Rs. 555 and intraday low of 536.75. The net turnover during the day was Rs. 88770446.

**US and Canada
**including European Free Trade Association (EFTA) and Balkan states
***including India, Russia and Commonwealth of Independent States (CIS)

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Infosys Expands announces the Opening of a New Studio in Berlin

Arcadia Biosciences and Shriram Bioseed achieve key milestone in Developing Extended Shelf Life Tomatoes

SML Isuzu Ltd board to approve first quarter results on Aug 9, 2018

Schneider Electric Infrastructure Ltd board to consider quarterly results on July 27, 2018

Merck Ltd calls for board meeting on Aug 7, 2018

Shree Digvijay Cement Company Ltd Q1 PAT up at Rs. 5.95 crore

Sagar Cements Ltd Q1 net profit lower at Rs. 5.82 crore

Omax Autos Ltd posts net profit of Rs. 0.52 crore in Q1

VLS Finance Ltd posts higher Q1 net profit of Rs. 3.63 crore

Hatsun Agro Product Ltd Q1 net profit higher at Rs. 37.85 crores

ABB India Ltd Q2 net profit climbs to Rs. 102.15 crores

Twentyfirst Century Management Services Ltd Q1 net profit at Rs. 5.43 crores

Aditya Birla Money Ltd Q1 consolidated PAT at Rs. 2.01 crore

Bajaj Finserv Ltd Q1 net profit vaults to Rs. 825.77 crores

G N A Axles Ltd Q1 PAT up at Rs. 14 crores

South India Paper Mills Ltd Q1 net profit climbs to Rs. 4.69 crores

Sterlite Tech delivers another strong quarter

Bajaj Finance posts highest ever quarterly consolidated profit of Rs. 836 crore

Simplex Mills Company Ltd calls for board meeting on Aug 1, 2018

Gujarat Sidhee Cement Ltd suspends operation of kiln due to rains

Sunil Healthcare Ltd calls for board meeting on Aug 13, 2018

CG Power and Industrial Solutions Ltd board to consider 1st quarter results on Aug 3, 2018

KG Denim Ltd board to consider first quarter results on Aug 1, 2018

UPL Limited board to announce quarterly results on July 31, 2018

Kopran Ltd board to approve 1st quarter results on Aug 8, 2018

JSW Holdings Limited calls for board meeting on Aug 4, 2018

Simplex Realty Ltd board to consider Q1 results on Aug 1, 2018

PFC to consider fund raising

TCS Positioned as a Leader in Life Sciences R&D BPO Services in IDC Marketscape

Karnataka Bank launches DigiLocker facility

Quick Heal Technologies Ltd calls for board meeting on Aug 8, 2018

Monsanto India Ltd board to consider quarterly results on Aug 6, 2018

RBL Bank Ltd - Q1 FY19 Operating review

Pudumjee Industries Ltd calls for board meeting on July 28, 2018

Trigyn Awarded - U.S. Army Picatinny Arsenal - Software Engineering Center Contract

Parag Milk Fods Limited Welcomes Government of India Announcement of 10% Export Subsidy

Edelweiss announces Rs.20,000 million Public Issue of Secured Redeemable NCDs

Sterlite Technologies Ltd Q1 net profit jumps to Rs. 128.48 crores

Bajaj Finance Ltd Q2 consolidated PAT soars to Rs. 835.89 crore

Kotak Mahindra Bank Q1 net profit climbs to Rs. 1574.48 crores

Menon Bearings Ltd Q1 PAT zooms to Rs. 7.19 crore

Integra Engineering India Ltd Q1 net profit at Rs. 1.04 crore

Apollo Tyres Ltd calls for board meeting on Aug 1, 2018

Artson Engineering Ltd receives order of Rs. 28.94 crores

RBL Bank Ltd - Q1 FY19 Performance highlights

NTPC Ltd board to consider quarterly results on July 28, 2018

NIIT launches pioneering Career Programs to match the changing talent requirements of global organizations

NCC Ltd board to announce Q1 results on Aug 10, 2018

Electrotherm India Ltd enters into settlement with IFC

LT Foods Ltd board to approve first quarter results on Aug 13, 2018

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018